The science of Durban, AIDS 2016

Area of Science:

• The 21st International AIDS Conference highlighted advancements in basic, clinical, prevention, law, policy, and implementation science for HIV/AIDS.
• Progress in scientific translation for HIV prevention, treatment, and care has reached 18 million individuals with antiviral therapy by mid-2016.

Background:

• Despite achievements, adult HIV incidence remains stable, increasing in specific regions and key populations, challenging current strategies.
• HIV cure research and preventive vaccine development show promise but require sustained investment and innovation.
• Clinical research has advanced with new diagnostics, agents, and regimens, yet faces challenges from complex patient populations and co-morbidities.

Framework:

• Pre-exposure prophylaxis (PrEP) and treatment as prevention show potential but face limitations in rollout and population-level impact.
• Addressing legal, policy, and human rights barriers is critical for vulnerable populations, including sexual and gender minorities, sex workers, people who inject drugs, and incarcerated individuals.

Implementation:

• Large-scale implementation of antiviral therapy has reached 18 million people.
• Rollout and impact of proven interventions like PrEP have been limited.
• Improving access to essential services for key populations remains a significant challenge.

Implications:

• Failure to address the needs of key populations risks undermining the overall HIV/AIDS response.
• Continued innovation in prevention tools and combination approaches is necessary for epidemic control.
• Unresolved issues in TB management and epidemic control require further attention within the complex patient populations.